Invention Grant
US08945548B2 Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
有权
抗IL12Rbeta1抗体及其在治疗自身免疫性和炎症性疾病中的应用
- Patent Title: Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
- Patent Title (中): 抗IL12Rbeta1抗体及其在治疗自身免疫性和炎症性疾病中的应用
-
Application No.: US14045276Application Date: 2013-10-03
-
Publication No.: US08945548B2Publication Date: 2015-02-03
- Inventor: Jose M. Carballido Herrera , Stefan Hartle , Christoph Heusser , Ingo Klagge , Andrea Polzer , Christoph Schwaerzler , Gabriela Wochnik-Veltrup
- Applicant: Jose M. Carballido Herrera , Stefan Hartle , Christoph Heusser , Ingo Klagge , Andrea Polzer , Christoph Schwaerzler , Gabriela Wochnik-Veltrup
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C12N9/02 ; C12Q1/66
Abstract:
The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
Public/Granted literature
- US20140120101A1 Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders Public/Granted day:2014-05-01
Information query
